Celoxica Limited — Investment Risk Analysis

1. Risk Rating: HIGH

The company is balance-sheet insolvent on a standalone basis, with shareholders' funds of -£71.7 million as at 31 December 2020 (versus -£70.3 million in 2019) and total liabilities of approximately £48 million, against share capital of just £120,230. This position is partially mitigated by a clean audit opinion, current filings, and majority ownership by a parent PLC, but the underlying solvency deficit is severe and cannot be overlooked.

2. Key Concerns

1. Deep structural insolvency: Net liabilities of ~£72 million mean the company cannot meet its obligations from its own resources. Accumulated losses have worsened year-on-year (-£1.4m movement between 2019 and 2020), indicating continued loss-making rather than recovery.
2. Total dependence on parent support: Celoxica Holdings Plc holds >75% of shares and voting rights. The auditor's unqualified going concern conclusion strongly suggests liabilities are predominantly intra-group and/or supported by a parent comfort arrangement. If group support were withdrawn, the entity would likely be unable to continue. The standalone credit risk is therefore effectively the group's credit risk.
3. Stale financial visibility: The detailed financials provided end at FY2020, yet filing data indicates accounts have been made up to December 2025. Five years of performance are unaccounted for in this dataset — the current position could have materially improved or deteriorated.

3. Positive Indicators

• Longevity and continuity: Incorporated in 1996, with nearly three decades of continuous operation and a single name change (2000).
• Compliance record is clean: No overdue accounts or confirmation statements; filings current through 2025/2026.
• Voluntary audit with unqualified opinion: Despite being small-company exempt, the 2020 accounts were fully audited by Blick Rothenberg Audit LLP, with no going concern material uncertainty raised. This is a meaningful governance signal.
• Group backing: Ownership by a holdings PLC provides a potential funding backstop and governance oversight.
• Governance basics in place: Two directors, a company secretary, and D&O liability insurance maintained.

4. Due Diligence Notes

• Obtain FY2021–FY2025 accounts — essential to establish the current trajectory of the deficit and whether losses have continued.
• Obtain Celoxica Holdings Plc consolidated accounts and confirm in writing the existence, terms, and enforceability of any parent support letter. Determine the split of the £48m liabilities between intercompany and third-party creditors — this fundamentally changes the risk picture.
• Preference shares: The XBRL tagging references a preference share class alongside ordinary shares. Establish who holds these, their rights, and any redemption or dividend obligations that could rank ahead of other stakeholders.
• Cash flow reality: Balance sheet data alone cannot confirm liquidity. Request management accounts, bank facility details, and evidence of how operating cash needs are funded.
• R&D tax credits: The auditor specifically flagged "errors in the calculation of tax credit claims" as a focus area. Verify the history of R&D claims and whether any HMRC enquiries or clawbacks have occurred.
• Business substance: The current SIC (63110 — data processing/hosting) differs from the company's historical identity (the name change from Embedded Solutions Ltd suggests past pivots). Confirm actual trading activity, revenue sources, and customer concentration.
• Registers check: Review charges/mortgages registered against the company and confirm no director disqualifications or group insolvency events (none appear in the data provided, but this should be verified directly).